Regeneron's founders focused on building technology platforms for nearly a decade before their first major drug hit. This extreme long-term vision was designed to solve the industry's recurring patent cliff problem by creating a sustainable innovation engine, taking almost 24 years to achieve profitability.

Over 20 years, Alnylam raised $7.5 billion. Remarkably, this was evenly split between equity financing from capital markets and non-dilutive funding from pharmaceutical partnerships. This balanced strategy was essential for financing a long, capital-intensive R&D journey while managing shareholder dilution.

The founder of Project Insulin reveals it took five and a half years of work—primarily fundraising and planning—just to sign the contract with a CDMO to begin drug development. This highlights the immense, often invisible, runway required before the 'real' scientific work starts, demanding extreme patience and long-term commitment.

Phillip Sharp explains that the decision to co-found Alnylam was driven by the enormous potential of RNAi to treat countless diseases. This massive upside of changing medicine dwarfed the downside risk of the company failing, making it a compelling venture despite the odds.

The long history of now-commonplace technologies like monoclonal antibodies serves as a crucial reminder for the biotech industry. What appears to be an overnight success is often the culmination of decades of hard, incremental scientific work, highlighting the necessity of patience and long-term perspective.

While large pharma companies invested heavily in RNAi and failed to produce candidates, Alnylam maintained a singular focus. They pushed their technology into human trials to learn and validate it, ultimately succeeding where better-funded competitors with a less focused, product-driven approach failed.

The high probability of success for Alnylam's drugs seems simple now but was the result of years of work. They had to perfect a delivery modality, prove its safety, and identify validated targets in an accessible tissue (the liver). Only after solving these three monumental challenges did drug development become repeatable.

The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.

Companies tackling moonshots like autonomous vehicles (Waymo) or AGI (OpenAI) face a decade or more of massive capital burn before reaching profitability. Success depends as much on financial engineering to maintain capital flow as it does on technological breakthroughs.